ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 606

Characteristics Of Lupus Nephritis:  Data From a Large Multicenter Registry Of Patients With Systemic Lupus Erythematosus

Diane L. Kamen1, Graciela S. Alarcon2, Jill P. Buyon3, Mary Anne Dooley4, Richard A. Furie5, David S. Pisetsky6 and Tammy O. Utset7, 1Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 2Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, 5The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 6Department of Medicine, Duke University Medical Center, Durham, NC, 7Rheumatology, University of Chicago Medical Center, Chicago, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Hydroxychloroquine, lupus nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Renal disease is strongly associated with morbidity and mortality among SLE patients. We utilized the Lupus Clinical Trials Consortium, Inc. longitudinal registry of SLE patients from 16 academic lupus centers to estimate prevalence and incidence of renal disease and associated differences in demographics, comorbidities, biopsy rates, and therapeutic exposures.

Methods:

Patients were consecutively enrolled and followed at outpatient visits by participating rheumatologists.  Lupus nephritis (LN) was defined by ACR Classification Criteria. Damage (end-stage renal disease (ESRD), proteinuria (≥3.5 gm/d), low GFR) was determined by SLICC Damage Index (SDI). Descriptive statistics, chi square, Fisher’s exact, and ANOVA was used as appropriate to compare disease characteristics.  Multivariate regression modeling was used to adjust for disease duration and race. P <0.05 was considered statistically significant.

Results:

Of 1507 patients, 639 (42.4%) had LN at registry enrollment.  Mean age was 41.3 yrs, disease duration 9.4 yrs, 5.5 ACR Criteria, 2.6 SLEDAI score, and 1.1 SLICC-DI score. LN patients were younger at SLE diagnosis (26.2 vs 32.1 yrs, p<0.01) and 11.9% LN vs 6.0% non-LN patients were male (p<0.01).  LN prevalence in non-Hispanic Blacks (49%) and Asians (53%) was higher than non-Hispanic Whites (32%, p<0.01 ).

LN and non-LN patients had similar prevalence of cardiovascular disease (7.4 vs. 8.0%, p=0.67), though LN patients had higher prevalence of hypertension (57.0% vs. 29.5%, p<0.01), hyperlipidemia (23.2% vs. 11.4%, p<0.01), and pre-eclampsia (10.0 vs. 5.7%, p<0.01).  Asians with LN had a lower renal biopsy rate of 66.2% compared to non-Hispanic Blacks (79.3%, p=0.02). LN patients with a confirmatory renal biopsy were more likely to have received cyclophosphamide (CTX, 51.4% vs 34.4%, p=0.0002), mycophenolate (MMF, 75.0% vs 56.9%, p<0.0001), or both CTX and MMF in the past (38.4 vs 21.3%, p<0.0001) compared to non-biopsied LN patients.

Of 868 non-LN patients at enrollment, 10 (1.2%) developed LN over an average of 1.8 yrs follow-up.  Of the 1348 with no renal damage at enrollment, 28 (2.1%) developed renal damage over an average of 1.8 yrs follow-up. Patients without renal damage at enrollment taking hydroxychloroquine (72.0% overall) had subsequently lower renal damage incidence (1.3% vs 4.0%, p=0.0023). Patients on MMF (26.3% overall) had higher incidence of renal damage (3.7% vs 1.5%, p=0.014) but no difference seen with CTX or azathioprine.

At enrollment, 55 patients had ESRD with an additional 14 incident cases over 2.5 yrs follow-up.  Eight patients (12%) with low GFR vs 0.04% without low GFR by SDI at enrollment progressed to ESRD over an average of 1.8 yrs follow-up.  Seven patients (15%) with proteinuria vs 0.5% without proteinuria by SDI at enrollment progressed to ESRD over an average of 1.8 yrs follow-up.

Conclusion:

This study describes prevalent and incident characteristics of LN and renal damage among a large cohort of patients with SLE. Consistent with other cohorts, LN rates vary by race and hydroxychloroquine use appears to help protect from renal damage.  Prior renal damage associated with progression to ESRD emphasizes the importance of early identification of high-risk SLE patients.


Disclosure:

D. L. Kamen,
None;

G. S. Alarcon,
None;

J. P. Buyon,
None;

M. A. Dooley,
None;

R. A. Furie,
None;

D. S. Pisetsky,
None;

T. O. Utset,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristics-of-lupus-nephritis-data-from-a-large-multicenter-registry-of-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology